Professor Robert Gray

  • Professor of Respiratory Medicine (Immunology & Infection)

Biography

Robert Gray is Professor of Respiratory Medicine at the School of Infection & Immunity and an Honorary Consultant Respiratory Physician at NHS GGC. He completed training in respiratory medicine in Edinburgh and then held consecutive intermediate (Wellcome) and senior (NRS/CSO) fellowships prior to his appointment in Glasgow.

Research interests

1. Spontaneous lung repair processes in the CF and other lung diseases. We are using ex-vivo models to study how lung damage occurs and repairs. By understanding how spontaneous tissue repair occurs, we will be able to develop new treatments to support the repair of damaged lung tissue.

2. Inflammation in lung disease: By mapping out the inflammation process in CF using tissue from people with CF and other lung diseases, we will allow the development of future anti-inflamatory treatments to be driven by scientific understanding. We will use new technologies, such as single cell RNA sequecung and spatial biology, to achieve these aims.

3. Defining the role of calprotectin in health and disease in the lung and other tissues: The Gray Lab has studied S100 proteins in the lung for the past 15 years; firstly, as biomarkers, and now as a potential drug target.

 

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2020 | 2018 | 2016
Number of items: 11.

2024

Law, S. M., Hardisty, G., Gillan, J. L., Robinson, N. J., Davidson, D. J., Whyte, M. K.B., Dransfield, I. and Gray, R. D. (2024) Neutrophil extracellular traps are associated with airways inflammation and increased severity of lung disease in Cystic Fibrosis. ERJ Open Research, 10(6), 312-2024. (doi: 10.1183/23120541.00312-2024) (PMID:39624379)

Skinner, W. H., Robinson, N., Hardisty, G. R., Gray, R. D. and Campbell, C. J. (2024) SERS microsensors for the study of pH regulation in cystic fibrosis patient-derived airway cultures. ACS Sensors, 9(5), pp. 2550-2557. (doi: 10.1021/acssensors.4c00279) (PMID:38659220) (PMCID:PMC11129347)

2023

Gray, R. (2023) Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respiratory Medicine, 11(10), pp. 931-916. (doi: 10.1016/S2213-2600(23)00324-7) (PMID:37699420)

Gillan, J. L. et al. (2023) CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages. Science Advances, 9(21), eadg5128. (doi: 10.1126/SCIADV.ADG5128) (PMID:37235648) (PMCID:PMC10219589)

Skinner, W. H., Robinson, N., Hardisty, G. R., Fleming, H., Geddis, A., Bradley, M., Gray, R. D. and Campbell, C. J. (2023) SERS microsensors for pH measurements in the lumen and ECM of stem cell derived human airway organoids. Chemical Communications, 59(22), pp. 3249-3252. (doi: 10.1039/D2CC06582G) (PMID:36815668)

2022

Carter, S. C. et al. (2022) Acute pulmonary exacerbation phenotypes in patients with cystic fibrosis. Annals of the American Thoracic Society, 19(11), pp. 1818-1826. (doi: 10.1513/ANNALSATS.202111-1266OC) (PMID:35713619) (PMCID:PMC9667812)

Gray, R. D. et al. (2022) Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. Thorax, 73(2), pp. 134-144. (doi: 10.1136/thoraxjnl-2017-210134) (PMID:28916704) (PMCID:PMC5771859)

2021

Hardisty, G. R., Law, S. M., Carter, S., Grogan, B., Singh, P. K., McKone, E. F. and Gray, R. D. (2021) Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations. European Respiratory Journal, 57(1), 2002161. (doi: 10.1183/13993003.02161-2020) (PMID:32855222) (PMCID:PMC7817919)

2020

Gillan, J. L., Davidson, D. J. and Gray, R. D. (2020) Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages. European Respiratory Journal, 57(6), 2003502. (doi: 10.1183/13993003.03502-2020) (PMID:33303535)

2018

Gray, R. D. (2018) NETs in pneumonia: is just enough the right amount? European Respiratory Journal, 51(4), 1800619. (doi: 10.1183/13993003.00619-2018) (PMID:29700108)

2016

Meijer, L. et al. (2016) Modulating innate and adaptive immunity by (R)-Roscovitine: potential therapeutic opportunity in cystic fibrosis. Journal of Innate Immunity, 8(4), pp. 330-349. (doi: 10.1159/000444256) (PMID:26987072) (PMCID:PMC4800827)

This list was generated on Sat Jan 18 21:58:50 2025 GMT.
Jump to: Articles
Number of items: 11.

Articles

Law, S. M., Hardisty, G., Gillan, J. L., Robinson, N. J., Davidson, D. J., Whyte, M. K.B., Dransfield, I. and Gray, R. D. (2024) Neutrophil extracellular traps are associated with airways inflammation and increased severity of lung disease in Cystic Fibrosis. ERJ Open Research, 10(6), 312-2024. (doi: 10.1183/23120541.00312-2024) (PMID:39624379)

Skinner, W. H., Robinson, N., Hardisty, G. R., Gray, R. D. and Campbell, C. J. (2024) SERS microsensors for the study of pH regulation in cystic fibrosis patient-derived airway cultures. ACS Sensors, 9(5), pp. 2550-2557. (doi: 10.1021/acssensors.4c00279) (PMID:38659220) (PMCID:PMC11129347)

Gray, R. (2023) Understanding and addressing the needs of people with cystic fibrosis in the era of CFTR modulator therapy. Lancet Respiratory Medicine, 11(10), pp. 931-916. (doi: 10.1016/S2213-2600(23)00324-7) (PMID:37699420)

Gillan, J. L. et al. (2023) CAGE sequencing reveals CFTR-dependent dysregulation of type I IFN signaling in activated cystic fibrosis macrophages. Science Advances, 9(21), eadg5128. (doi: 10.1126/SCIADV.ADG5128) (PMID:37235648) (PMCID:PMC10219589)

Skinner, W. H., Robinson, N., Hardisty, G. R., Fleming, H., Geddis, A., Bradley, M., Gray, R. D. and Campbell, C. J. (2023) SERS microsensors for pH measurements in the lumen and ECM of stem cell derived human airway organoids. Chemical Communications, 59(22), pp. 3249-3252. (doi: 10.1039/D2CC06582G) (PMID:36815668)

Carter, S. C. et al. (2022) Acute pulmonary exacerbation phenotypes in patients with cystic fibrosis. Annals of the American Thoracic Society, 19(11), pp. 1818-1826. (doi: 10.1513/ANNALSATS.202111-1266OC) (PMID:35713619) (PMCID:PMC9667812)

Gray, R. D. et al. (2022) Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. Thorax, 73(2), pp. 134-144. (doi: 10.1136/thoraxjnl-2017-210134) (PMID:28916704) (PMCID:PMC5771859)

Hardisty, G. R., Law, S. M., Carter, S., Grogan, B., Singh, P. K., McKone, E. F. and Gray, R. D. (2021) Ivacaftor modifies cystic fibrosis neutrophil phenotype in subjects with R117H residual function CFTR mutations. European Respiratory Journal, 57(1), 2002161. (doi: 10.1183/13993003.02161-2020) (PMID:32855222) (PMCID:PMC7817919)

Gillan, J. L., Davidson, D. J. and Gray, R. D. (2020) Targeting cystic fibrosis inflammation in the age of CFTR modulators: focus on macrophages. European Respiratory Journal, 57(6), 2003502. (doi: 10.1183/13993003.03502-2020) (PMID:33303535)

Gray, R. D. (2018) NETs in pneumonia: is just enough the right amount? European Respiratory Journal, 51(4), 1800619. (doi: 10.1183/13993003.00619-2018) (PMID:29700108)

Meijer, L. et al. (2016) Modulating innate and adaptive immunity by (R)-Roscovitine: potential therapeutic opportunity in cystic fibrosis. Journal of Innate Immunity, 8(4), pp. 330-349. (doi: 10.1159/000444256) (PMID:26987072) (PMCID:PMC4800827)

This list was generated on Sat Jan 18 21:58:50 2025 GMT.